Edition:
United States

Amyris Inc (AMRS.OQ)

AMRS.OQ on NASDAQ Stock Exchange Global Select Market

5.59USD
22 Jun 2018
Change (% chg)

$0.09 (+1.64%)
Prev Close
$5.50
Open
$5.52
Day's High
$5.64
Day's Low
$5.52
Volume
2,155,279
Avg. Vol
158,965
52-wk High
$7.30
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Amyris Says Novvi LLC and Chevron Entered Agreement
Friday, 18 May 2018 08:30am EDT 

May 18 (Reuters) - Amyris Inc ::AMYRIS SUSTAINABLE LUBRICANTS JOINT VENTURE COMPANY, NOVVI, AND CHEVRON ENTER AGREEMENT TO DEVELOP AND BRING TO MARKET NEW RENEWABLE BASE OIL TECHNOLOGIES.AMYRIS INC - TERMS OF TRANSACTION WERE NOT DISCLOSED.AMYRIS INC - NOVVI LLC AND CHEVRON ENTERED INTO AGREEMENT TO JOINTLY DEVELOP AND BRING TO MARKET NOVEL RENEWABLE BASE OIL TECHNOLOGIES.  Full Article

Amyris Q1 GAAP Loss Per Share $1.79
Monday, 14 May 2018 04:00pm EDT 

May 14 (Reuters) - Amyris Inc ::AMYRIS CONTINUES STRONG MOMENTUM AND EXECUTION WITH 77% REVENUE GROWTH AND EXCEEDS GROSS MARGIN TARGET.Q1 NON-GAAP LOSS PER SHARE $0.52.Q1 GAAP LOSS PER SHARE $1.79.Q1 REVENUE $23 MILLION VERSUS $13 MILLION.  Full Article

Amyris Inc Files For Non-Timely 10-K With U.S. SEC
Monday, 2 Apr 2018 05:33pm EDT 

April 2 (Reuters) - Amyris Inc ::AMYRIS INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC.  Full Article

Amyris Reports Q4 Gaap Loss Per Share $0.17
Thursday, 15 Mar 2018 04:00pm EDT 

March 15 (Reuters) - Amyris Inc ::AMYRIS REPORTS ANOTHER STRONG QUARTER WITH SOLID OPERATING PERFORMANCE AND 2017 REVENUE OF $143.4 MILLION UP 113% OVER 2016.Q4 NON-GAAP EARNINGS PER SHARE $0.61.Q4 GAAP LOSS PER SHARE $0.17.Q4 REVENUE $80.6 MILLION VERSUS $22.2 MILLION.‍EXPECTS MORE THAN $10 MILLION OF POSITIVE EBITDA FOR 2018​.TOTAL GAAP REVENUE OUTLOOK OF APPROXIMATELY $185-$195 MILLION FOR 2018.  Full Article

Amyris posts Q3 GAAP loss of $1.14 per share
Tuesday, 14 Nov 2017 04:07pm EST 

Nov 14 (Reuters) - Amyris Inc :Amyris reports another strong quarter of product sales growth and expects strong finish for 2017.Q3 GAAP loss per share $1.14.Q3 revenue $24.2 million versus $26.5 million.Qtrly non-GAAP basic loss per share $‍0.81​.  Full Article

Amyris Inc enters into agreement with Koninklijke DSM N.V.
Thursday, 5 Oct 2017 08:30am EDT 

Oct 5 (Reuters) - Amyris Inc :Amyris enters into product development and production agreement with Royal DSM for human nutrition ingredient.Amyris Inc - ‍entered into a product development and production agreement for a new class of human nutrition ingredients with Koninklijke DSM N.V.​.Amyris Inc - partnership announced is focused on developing ingredient for market introduction in 2019.  Full Article

Amyris enters into second major product development with Royal DSM
Tuesday, 26 Sep 2017 08:30am EDT 

Sept 26 (Reuters) - Amyris Inc :Amyris Inc enters into second major product development and production agreement with Royal DSM.Amyris Inc - ‍has entered into a product development and production agreement for vitamin A with Koninklijke DSM N.V.​.Amyris Inc - DSM is partnering with Amyris to fund development of technology to produce vitamin A​.  Full Article

Amyris Q2 loss per share $0.46
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Amyris Inc :Amyris delivers another strong quarter with revenue of $25.7 million and product sales increase of 159% over 2nd quarter of 2016.Q2 loss per share $0.46.Q2 revenue rose 168 percent to $25.7 million.Says Q2 2017 product sales of $12.7 million, up 159% over $4.9 million for Q2 2016.  Full Article

Amyris says second tranche of $50 mln in a private placement days is being led by a $25-mln investment from Koninklijke​
Thursday, 3 Aug 2017 08:30am EDT 

Aug 3 (Reuters) - Amyris Inc :Amyris announces agreements for $50 million in second tranche of equity financing, exceeding previous target of $95 million.Amyris Inc - ‍second tranche of $50 million in a private placement days is being led by a $25-million investment from Koninklijke DSM N.V.​.Amyris Inc - ‍remaining $25 million of $50 million private placement contributed by Vivo Capital, a healthcare investment firm​.Amyris Inc - ‍following close of tranche, Vivo Capital will be granted an Amyris board seat and DSM gains an additional board seat​.  Full Article

Biossance says will expand to Sephora in over 60 Sephora locations across Canada
Wednesday, 26 Jul 2017 08:30am EDT 

July 26 (Reuters) - Amyris Inc ;:Biossance says will expand to Sephora in over 60 Sephora locations across Canada in January 2018.  Full Article

BRIEF-Temasek Holdings Reports 8.9 Pct Stake In Amyris Inc

* TEMASEK HOLDINGS (PRIVATE) LIMITED REPORTS 8.9 PERCENT STAKE IN AMYRIS INC AS OF MAY 22, 2018 - SEC FILING